Australia markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7290+0.0490 (+1.83%)
As of 01:24PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 559.54M
Enterprise value 263.60M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.02k
Price/book (mrq)1.21
Enterprise value/revenue 3.03k
Enterprise value/EBITDA -1.04

Trading information

Stock price history

Beta (5Y monthly) 0.85
52-week change 3-45.97%
S&P500 52-week change 323.95%
52-week high 35.7800
52-week low 32.0100
50-day moving average 32.5552
200-day moving average 33.2710

Share statistics

Avg vol (3-month) 32.76M
Avg vol (10-day) 32.48M
Shares outstanding 5208.78M
Implied shares outstanding 6208.78M
Float 8124.56M
% held by insiders 117.54%
% held by institutions 164.47%
Shares short (28 June 2024) 441.38M
Short ratio (28 June 2024) 411.97
Short % of float (28 June 2024) 427.92%
Short % of shares outstanding (28 June 2024) 419.82%
Shares short (prior month 31 May 2024) 440.57M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-315,927.27%

Management effectiveness

Return on assets (ttm)-26.71%
Return on equity (ttm)-55.48%

Income statement

Revenue (ttm)87k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-26.70%
Gross profit (ttm)N/A
EBITDA -270.66M
Net income avi to common (ttm)-292.3M
Diluted EPS (ttm)-1.7800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)384.86M
Total cash per share (mrq)2.25
Total debt (mrq)95.85M
Total debt/equity (mrq)20.77%
Current ratio (mrq)12.80
Book value per share (mrq)2.71

Cash flow statement

Operating cash flow (ttm)-226.99M
Levered free cash flow (ttm)-134.9M